Euroopa Liit -
islandi -
EMA (European Medicines Agency)
ontilyv
bial portela & companhia s.a. - opicapone - parkinsonsveiki - anti-parkinsonslyf - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.
Island -
islandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
furix tafla 40 mg
orifarm healthcare a/s - furosemidum inn - tafla - 40 mg
Island -
islandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
furix tafla 20 mg
orifarm healthcare a/s - furosemidum inn - tafla - 20 mg
Island -
islandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
budesonide alvogen (budesonide teva) dreifa í eimgjafa 0,5 mg/ml
alvogen ehf. - budesonidum inn - dreifa í eimgjafa - 0,5 mg/ml
Island -
islandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
emla (emla) krem 25+25 mg/g
aspen pharma trading limited - lidocainum inn; prilocainum inn - krem - 25+25 mg/g
Island -
islandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
ceftriaxona normon innrennslisstofn, lausn 2000 mg
laboratorios normon, s.a. - ceftriaxonum dínatríum - innrennslisstofn, lausn - 2000 mg
Island -
islandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
ceftriaxona normon stungulyfs-/innrennslisstofn og leysir, lausn 1000 mg
laboratorios normon, s.a. - ceftriaxonum dínatríum - stungulyfs-/innrennslisstofn og leysir, lausn - 1000 mg
Island -
islandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
clariscan stungulyf, lausn 0,5 mmól/ml
ge healthcare as - acidum gadotericum inn - stungulyf, lausn - 0,5 mmól/ml
Island -
islandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
clariscan stungulyf, lausn í áfylltri sprautu 0,5 mmól/ml
ge healthcare as - acidum gadotericum inn - stungulyf, lausn í áfylltri sprautu - 0,5 mmól/ml
Island -
islandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
tambocor tafla 100 mg
viatris aps - flecainidum acetat - tafla - 100 mg